Chang Yu has been Director of HCLS at AWS Greater China since 2019, leveraging expertise in HPC, bioinformatics, and genomic analysis to connect technology with healthcare. He leads Multi-Agent systems research in pharmaceutical sciences from discovery to clinical trials. Previously, he held leadership roles at NVIDIA, Intel, and BGI, driving computational solutions for genomics and precision medicine. He mentors at Sichuan University, teaches at CUHK (Shenzhen), and conducted research at Hong Kong University. He holds an MBA from HKUST and a Master’s in Biomedical Engineering. Author of 29 publications and two patents, he received the 2011 Shenzhen Technology Innovation Award and was named a Highly Cited Researcher by Clarivate in 2019.

Professor Shinya Yamamoto has contributed to the biopharmaceutical industry for over 20 years, with expertise in innovation management, digital health, clinical research, regulatory affairs, and business development. He holds degrees in Chemistry, Molecular Biology, and Technology & Innovation Management (PhD). He is General Manager at Deep Intelligent Pharma K.K. and serves as Guest Professor at Osaka University Graduate School of Medicine and Hospital, Visiting Professor at Kobe University and the Professional University of Information and Management for Innovation, Specially Appointed Professor at Tohoku University Smart-Aging Research Center, and Part-Time Instructor in the Global MBA Program at Hosei Business School.

Dr. Li Xing is a pharmaceutical veteran with over 12 years of experience at multinational companies including Pfizer, Sanofi, and Johnson & Johnson, where she served on J&J China's new drug development leadership team. A graduate of Peking University's School of Pharmaceutical Sciences, she founded Deep Intelligent Pharma in 2017 to leverage AI in transforming pharmaceutical R&D. Under her leadership, the company aims to “make drug development accessible to all and bring the light of life to patients,” building infrastructure for global firms to embrace intelligent drug discovery. Her blend of pharmaceutical expertise and AI vision positions her at the forefront of the industry’s digital transformation.

Mr. Jin is currently Head, Regulatory Competency Center Asia Pacific, Middle East and Africa (APMA) at Sandoz Asia Pacific Pharmaceutical Pte. Ltd. He is responsible for all regulatory related activities in Asia Pacific, Middle East and Africa (APMA). Mr. Jin has been working in regulatory affairs field in pharmaceutical industry for more than 20 years. He has extensive expertise in regulatory affairs and in the drug development in the region. Prior to joining Sandoz, he worked in Abbott, AbbVie, Takeda, Parexel and GE Healthcare. Mr. Jin is trained as a pharmacist with business degree.

Young Joo Park serves as Vice President, overseeing operations in Korea, Singapore, and Southeast Asia. With over 25 years of experience at MSD and Sanofi, she has excelled in organizational management and clinical trials across diverse therapeutic areas, including oncology, cardiovascular disease, endocrinology, and infectious diseases. She also worked for the Korea National Enterprise for Clinical Trials (KoNECT), an affiliate of the Korean Ministry of Health and Welfare, as Head of Business Development and Global Cooperation. Most recently, she served as CEO of the U.S. subsidiary of a gene therapy company. Young Joo Park holds a Ph.D. in Epidemiology and an MPH degree from Seoul National University.